Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease

Clinical Neurology and Neurosurgery

Volumn 111, Issue 4, 2009, Pages 341-344

  Asai, Hirohide ^a   Hirano, Makito ^a   Furiya, Yoshiko ^a   Udaka, Fukashi ^b   Morikawa, Masami ^a   Kanbayashi, Takashi ^c   Shimizu, Tetsuo ^c   Ueno, Satoshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b SUMITOMO HOSPITAL   (Japan)

^c AKITA UNIVERSITY   (Japan)

Author keywords

Dopaminergic receptor; Excessive daytime sleepiness; Narcolepsy; Orexin; Pergolide; Sleep attacks

Indexed keywords

DOPA DECARBOXYLASE INHIBITOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; LEVODOPA; OREXIN; PERGOLIDE; PRAMIPEXOLE;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DISEASE DURATION; DRUG DOSE INCREASE; FEMALE; HUMAN; INCIDENCE; MALE; PARKINSON DISEASE; SLEEP; SLEEP DISORDER; STIMULATION;

ADULT; AGED; DOPAMINE AGONISTS; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEUROPEPTIDES; PARKINSON DISEASE; PERGOLIDE; RADIOIMMUNOASSAY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS;

EID: 63449093381     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2008.11.007     Document Type: Article

References (26)

1. Brodsky M.A., Godbold J., Roth T., and Olanow C.W. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 18 (2003) 668-672
2. Tracik F., and Ebersbach G. Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings. Mov Disord 16 (2001) 500-506
3. Paus S., Brecht H.M., Köster J., Seeger G., Klockgether T., and Wüllner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 18 (2003) 659-667
4. Fronczek R., Overeem S., Lee S.Y., Hegeman I.M., van Pelt J., van Duinen S.G., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 130 (2007) 1577-1585
5. Thannickal T.C., Lai Y.Y., and Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130 (2007) 1586-1595
6. Drouot X., Moutereau S., Nguyen J.P., Lefaucheur J.P., Créange A., Remy P., et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 61 (2003) 540-543
7. Arnulf I., Bonnet A.M., Damier P., Bejjani B.P., Seilhean D., Derenne J.P., et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 55 (2000) 281-288
8. Lee B.F., Chiu N.T., Kuang Yang Y., and Lin Chu C. The relation between striatal dopamine D2/D3 receptor availability and sleep quality in healthy adults. Nucl Med Commun 28 (2007) 401-406
9. Barik S., and de Beaurepaire R. Dopamine D3 modulation of locomotor activity and sleep in the nucleus accumbens and in lobules 9 and 10 of the cerebellum in the rat. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 718-726
10. Bubser M., Fadel J.R., Jackson L.L., Meador-Woodruff J.H., Jing D., and Deutch A.Y. Dopaminergic regulation of orexin neurons. Eur J Neurosci 21 (2005) 2993-3001
11. Alberto C.O., Trask R.B., Quinlan M.E., and Hirasawa M. Bidirectional dopaminergic modulation of excitatory synaptic transmission in orexin neurons. J Neurosci 26 (2006) 10043-10050
12. Brusa L., Tiraboschi P., Koch G., Peppe A., Pierantozzi M., Ruggieri S., et al. Pergolide effect on cognitive functions in early-mild Parkinson's disease. J Neural Transm 112 (2005) 231-237
13. Hughes A.J., Daniel S.E., Kilford L., and Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 (1992) 181-184
14. Homann C.N., Wenzel K., Suppan K., Ivanic G., Kriechbaum N., Crevenna R., et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 324 (2002) 1483-1487
15. Kanbayashi T., Inoue Y., Kawanishi K., Takasaki H., Aizawa R., Takahashi K., et al. CSF hypocretin measures in patients with obstructive sleep apnea. J Sleep Res 12 (2003) 339-341
16. Linazasoro G. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease. J Neurol 251 March (2004) 335-339
17. McGeer P.L., and Zeldowicz L.R. Administration of dihydroxyphenylalanine to parkinsonian patients. Can Med Assoc J 15 (1964) 463-466
18. Mear J.Y., Barroche G., de Smet Y., Weber M., Lhermitte F., and Agid Y. Pergolide in the treatment of Parkinson's disease. Neurology 34 (1984) 983-986
19. Fantini M.L., Gagnon J.F., Filipini D., and Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology 61 (2003) 1418-1420
20. The European Agency for the Evaluation of Medical Products. Evaluation of medicines for human use. CPMP position statement: dopaminergic substance and sudden onset of sleep. Available at: http://www.emea.eu.int/pdfs/human/press/pos/057802.pdf.2002.
21. Ferreira J.J., Thalamas C., Montastruc J.L., Castro-Caldas A., and Rascol O. Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients. J Neurol 248 (2001) 426-427
22. Yasui K., Inoue Y., Kanbayashi T., Nomura T., Kusumi M., and Nakashima K. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 250 (2006) 120-123
23. Ripley B., Overeem S., Fujiki N., et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 57 (2001) 2253-2258
24. Ferreira J.J., Galitzky M., Montastruc J.L., and Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet 355 (2000) 1333-1334
25. Ulivelli M., Rossi S., Lombardi C., Bartalini S., Rocchi R., Giannini F., et al. Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD. Neurology 58 (2002) 462-465
26. Tracik F., and Ebersbach G. Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings. Mov Disord 16 (2001) 500-506